Piribedil hydrochloride (intraperitoneal injection, 5, 15, 40 mg/kg ) alleviates the L-DOPA-induced dyskinesias in rats model of Parkinson’s disease[2].
Piribedil hydrochloride (oral gavage, 4-5 mg/kg, daily for 2 weeks) increases locomotor activity and reversal of motor deficits in adult common marmosets[3].
Piribedil hydrochloride (oral gavage, 150 mg/kg, daily for 21 days) inhibits MLL-r tumor growth and decreases the expression of MLL1 target genes in MV4;11 tumor xenografts[4].
| Animal Model: | Rat model of Parkinson’s disease[2] |
| Dosage: | 5, 15, 40 mg/kg |
| Administration: | Intraperitoneal injection, administered 5 min before administration of L-DOPA. |
| Result: | Reduced turning behaviour and AD (axial dystonia), OD (orolingual dyskinesia) and FD (forelimb dyskinesia) at 5 and 40 mg/kg.
Increased LD (locomotive dyskinesias) at the 40 mg/kg.
|
| Animal Model: | Adult common marmosets[3] |
| Dosage: | 4-5 mg/kg |
| Administration: | Oral gavage, daily for 2 weeks |
| Result: | Increased vigilance and alertness and reversed the downregulation of preprotachykinin mRNA induced by MPTP in rostral and caudal striatum. |
